Eris Lifesciences Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025, showcasing steady growth in its pharmaceutical business. The Board of Directors approved the results in their meeting held on February 13, 2026.

Financial Performance Overview

The company delivered robust performance across key financial metrics during the third quarter of FY26. Revenue growth was driven primarily by increased product sales, while the company maintained its focus on operational efficiency.

Nine-Month Performance

For the nine-month period ended December 31, 2025, Eris Lifesciences demonstrated consistent growth momentum. The company's consolidated revenue from operations increased to ₹2,372.86 crore from ₹2,188.34 crore in the corresponding period of the previous year.

Impact of New Labour Codes

The company recorded exceptional items of ₹17.24 crore during Q3 FY26 due to the implementation of new labour codes by the Government of India, effective November 21, 2025. These codes consolidated multiple existing labour legislations into a unified framework, resulting in increased gratuity and leave liabilities arising from changes in the definition of "wages" for employees and contract labours.

Corporate Actions and Developments

Subsequent to the quarter end, on January 16, 2026, the company completed a significant transaction involving Swiss Parenterals Limited. Eris Lifesciences allotted 23,06,372 fully paid-up equity shares at an issue price of ₹1835.35 per share through private placement, acquiring the remaining 30% stake in Swiss Parenterals Limited, making it a wholly-owned subsidiary.

Key Financial Ratios

The company maintained healthy financial ratios during the quarter:

The company's debt-equity ratio improved to 0.67 times from 0.79 times in the previous year, indicating better capital structure management. The interest service coverage ratio strengthened to 4.33 times, reflecting improved earnings relative to finance costs.

Eris Lifesciences has formally notified the stock exchanges about its upcoming board meeting scheduled for February 13, 2026. The meeting will focus on reviewing and approving the company's quarterly financial performance for the third quarter of fiscal year 2026.

Board Meeting Details

The pharmaceutical company's Board of Directors will convene to consider and approve both standalone and consolidated unaudited financial results. The meeting will cover the financial performance for two key periods:

Trading Window Restrictions

Eris Lifesciences has implemented trading window restrictions in accordance with regulatory requirements. The company had previously informed stakeholders about these measures through its communication dated December 29, 2025.

Regulatory Compliance

The trading window closure aligns with the company's internal policy on 'Code of Conduct to Regulate, Monitor and Report Trading by its Designated Persons and immediate relatives of Designated Persons of the Company'. This measure ensures compliance with SEBI's insider trading regulations and maintains market integrity during the financial results announcement period.

Corporate Communication

The official notification was signed by Milind Talegaonkar, Company Secretary & Compliance Officer, and submitted to both BSE Limited and National Stock Exchange of India Limited. The company trades under security code 540596 on BSE and under the symbol ERIS on NSE.

Investors and stakeholders will need to wait until the board meeting concludes and results are officially declared before normal trading activities can resume for designated persons associated with the company.